Impact of biologicals on revision ESS numbers in CRSwNP in a tertiary care rhinology center | Synapse
March 3, 2026Open Access
Impact of biologicals on revision ESS numbers in CRSwNP in a tertiary care rhinology center
Key Points
Revision ESS rates have decreased due to the introduction of biologics in treatment.
The percentage of severe uncontrolled CRSwNP patients undergoing revision ESS has declined markedly with biologics.
This analysis took place at a tertiary care rhinology center, focusing on CRSwNP patient outcomes.
The findings suggest that biologics could enhance the overall management of CRSwNP cases.
Abstract
The advent of biologics reduced the number and percentage of severe uncontrolled CRSwNP patients undergoing revision ESS, in contrast to number and percentage of primary ESS.